22Jan 2023
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme)

Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme)

This study aimed to assess the safety and efficacy of tirzepatide in people of East Asian descent based on age and body mass index (BMI). At baseline, 73% of East Asian participants had a BMI of 25 kg/m2, or more significant, and 74% were younger than 65 . At week 52, tirzepatide induced a similar dose‐dependent reduction in HbA1c, waist circumference and BMI across subgroups. Across all BMI and age subgroups, mean absolute HbA1c decreases across the three doses ranged from 2.3% to 3.0%, and mean waist circumference reductions ranged from 4.3 to 9.8 cm. This post hoc analysis showed that once‐weekly tirzepatide had a similar safety and efficacy profile across BMI and age subgroups in East Asian participants.

  • #endo-diabetology

Like

Save

Share